Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Chronic Lymphoid Leukemia (CLL)

 

Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Investigator: John Pagel, MD, PhD;   Conditions: Leukemia, Lymphoma;    Status: Recruiting;   Study ID: NCT00918723

TRU-016 + Bendamustine vs. Bendamustine Alone for CLL (FH 2441)
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Chronic Lymphocytic Leukemia (CLL);    Status: Recruiting;   Study ID: NCT01188681

GS-1101 for Previously Treated Chronic Lymphocytic Leukemia (FH 2613)
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy for Patients With Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01539291

GS-1101 With Bendamustine and Rituximab for Chronic Lymphocytic Leukemia (FH 2597)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01569295

GDC-0853 Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (UW13044)
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Investigator: Stephen Douglas Smith, MD;   Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01991184

BMS-986016 for Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Investigator: Ajay K. Gopal, MD;   Conditions: Hematologic Neoplasms;    Status: Pending;   Study ID: NCT02061761

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Idelalisib + Bendamustine and Rituximab for Untreated CLL (9064)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01980888